Brainify.ai: Advancing Precision Neuroscience with AI

Brainify.ai is a pioneering full-stack neurotech platform developed by Neuroscience Software Inc. (dba Brainify.AI) that leverages the world’s largest EEG dataset—spanning 30 billion training data points from 120,000 patients—to deliver AI-driven insights for psychiatry, neurology, and neurodegenerative disorders. By combining a proprietary Foundational EEG AI Model with advanced deep learning, Brainify.ai transforms raw brain signals into actionable clinical and research data, enabling more accurate diagnostics, treatment response prediction, and patient monitoring. Its suite of solutions includes the BREEG wearable EEG device—the world’s smallest and smartest EEG headset—Dataset Hub for scalable data access, Companion Diagnostics (CDx) for drug development, and a powerful data engine that automates collection, integration, and standardization across diverse healthcare and biopharma environments. The platform supports the entire drug lifecycle, from translational research to post-approval commercialization, with proven capabilities in reducing placebo effects in clinical trials by up to 38% and improving antidepressant trial success rates. Backed by over 100 scientific publications, four patents, and clinically validated biomarkers, Brainify.ai is a trusted partner for healthcare providers, pharmaceutical companies, and research institutions aiming to bring precision medicine to brain health. The company’s mission, rooted in personal experience with depression, is to save lives by revolutionizing psychiatric care through innovation and data science.

Key Features:

• Foundational EEG AI Model: Deep learning-powered model trained on 30 billion data points to identify biomarkers for diagnostics, treatment prediction, and monitoring.
• Dataset Hub: Access to the largest global EEG dataset with 11 billion training samples from 150,000 patients across 317,000 sessions; 95% private, hardware-agnostic, and diverse in demographics and conditions.
• BREEG EEG Device: World’s smallest and smartest wearable EEG headset (~40g), wireless, with integrated amplifier and tablet interface—ideal for emergency departments, ICUs, and outpatient settings.
• Companion Diagnostics (CDx) Engine: Scalable, device-agnostic diagnostic tools that support patient stratification and biomarker-backed market expansion.
• AI-Integrated Analysis: Real-time, cloud-based AI analytics for automated EEG interpretation and structured clinical reporting.
• Drug Lifecycle Support: Offers research-as-a-service for biomarker discovery, placebo reduction, Phases II–III clinical trials, and post-approval commercialization.
• Placebo Biomarker Solution: Boosts study power by up to +38%, increasing the success rate of clinical trials.
• Translational Research Tools: Enables comparative EEG analysis and predictive modeling across diverse populations.
• Drug Rescue Program: Facilitates acquisition, application, conduct, and licensing of pharmaceutical assets to revive underperforming drug candidates.
• Continuous AI Updates: Regular software enhancements ensure the platform evolves with the latest research and clinical advancements.
• Privacy-Compliant Infrastructure: Adheres to GDPR and CalOPPA, with data processing compliant with international standards.

Pricing: Brainify.ai operates on a subscription and usage-based model, offering tailored solutions for biopharma and healthcare partners, with pilot programs and research access available through its research-as-a-service framework.

Conclusion: Brainify.ai stands at the forefront of AI-powered neuroscience, delivering transformative tools that bridge clinical innovation with real-world impact. Its robust platform, proven research outcomes, and commitment to improving mental health care make it an indispensable asset for advancing brain health and drug development.